Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer

NCT03379428 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

34

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms
Malignant Neoplasm of Breast

Interventions

DRUG: Trastuzumab
DRUG: Ibrutinib 560 mg
DRUG: Ibrutinib 840 mg
DRUG: Ibrutinib 420 mg

Sponsor

US Oncology Research

Collaborators

[object Object]
[object Object]